Original Research
Published on 21 Aug 2023
Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
in Cancer Molecular Targets and Therapeutics

- 2,004 views
- 1 citation